InMode (INMD)

• Market cap: $957M
• 1 day: -2.22%
• 5 days: -10.31%
• 1 month: -20.52%
• 3 months: -18.36%
• 6 months: -21.10%
• Year to date: -16.86%
• 1 year: -17.98%
• 5 years: 8.38%
• 10 years: 107.66%
• Sector: Healthcare
• Industry: Medical Devices

About: InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.

Employees: 599

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

0% less call options, than puts

Call options by funds: $28.8M | Put options by funds: $28.9M

2% less first-time investments, than exits

New positions opened: 44 | Existing positions closed: 45

2.55% less ownership

Funds ownership: 54.49% [Q3] → 51.93% (-2.55%) [Q4]

3% less funds holding

Funds holding: 252 [Q3] → 245 (-7) [Q4]

6% less capital invested

Capital invested by funds: $781M [Q3] → $734M (-$47.2M) [Q4]

34% less repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 98

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $15 6% upside
• Avg. target: $17.56 25% upside
• High target: $24 70% upside

4 analyst ratings

• positive: 1 25%
• neutral: 3 75%
• negative: 0 0%

Barclays Matt Miksic 48% 1-year accuracy 20 / 42 met price target	70% upside $24	Overweight Maintained	30 Apr 2025
UBS Danielle Antalffy 58% 1-year accuracy 7 / 12 met price target	15% upside $16.25	Neutral Maintained	29 Apr 2025
Canaccord Genuity Caitlin Cronin 21% 1-year accuracy 3 / 14 met price target	6% upside $15	Hold Maintained	29 Apr 2025
Jefferies Matthew Taylor 33% 1-year accuracy 1 / 3 met price target	6% upside $15	Hold Maintained	14 Apr 2025